Seeking Alpha

Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics

- New research supports updated estimates to U.S. prevalence of approximately 19,000 and approximately 29,000 in the EU and UK- “Deepening our understanding of the prevalence of ALSP – and learning ...
GEN

Rare Brain Disease ALSP Stalled by Microglia Replacement via Bone Marrow

It’s hard to overstate how crucial microglia are to brain health. These humble immune cells quietly patrol the central nervous system, clearing debris, pruning synapses, and maintaining myelin. But ...
Business Wire

Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today the enrollment of the ...
Nasdaq

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing ...

WATERTOWN, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Seeking Alpha

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...